Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCT2101
- Development stage
- Preclinical
- Lead developer
- Dragonboat Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
BCT2101 is a monoclonal antibody (mAb) drug candidate in development by Dragon Boat Pharmaceutical (also known as Dragonboat Biopharmaceutical Shanghai), a subsidiary of Guilin Sanjin Pharmaceutical. While the specific biological target and therapeutic indications for BCT2101 have not been publicly disclosed, the developer focuses on the research and development of biologics for gastrointestinal cancers, other oncology indications, and autoimmune diseases. The candidate is part of a pipeline that includes several other monoclonal and bispecific antibodies, though BCT2101 remains in the early stages of development with limited public data regarding its clinical progress.
Beyond the preview
Go deeper on BCT2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCT2101.